Mural Oncology plc (MURA) entered a merger agreement on August 20, 2025, to be acquired by XOMA Royalty Corp. (XOMA) in a deal valued at $36.2 million.
XRA 5 Corp., a subsidiary of XOMA Royalty, has agreed to acquire the entire issued share capital of Mural for cash.
Each Mural shareholder would receive a base cash price of $2.035 per share and may receive an additional cash amount per share of up to $0.205, which would be calculated based on the amount by which Mural’s Closing Net Cash exceeds its Estimated Closing Net Cash.
The base price of $2.035 per share represents a premium of 13.06% from the stock’s last close.
Mural Oncology is a Dublin-based biotech company that develops new cancer treatments using protein engineering, including its lead drug nemvaleukin alfa and other immune-based therapies.
XOMA Royalty is a biotechnology royalty aggregator that acquires future economic rights to early- and mid-stage therapeutic candidates licensed to pharma and biotech companies, supporting their development with non-dilutive funding.
Mural Oncology started exploring strategic alternatives in April. The stock was trading at $1.03 before the company engaged Lucid Capital Markets to act as its financial advisor in connection with the exploration of strategic alternatives.
The deal is expected to close by the end of 2025.
Lucid Capital Markets acted as financial advisor, and Wilmer Cutler Pickering Hale and Dorr, together with Arthur Cox, provided legal counsel to Mural Oncology. For XOMA Royalty, Davy Corporate Finance served as financial advisor, with Gibson, Dunn & Crutcher and Mason Hayes & Curran offering legal counsel.
For comprehensive details regarding this merger and acquisition transaction, please visit the Deal Metrics page here:
Deal Metrics for the acquisition of Mural Oncology plc (MURA) by XOMA Royalty Corp. (XOMA).
The Deal Metrics page for each merger or acquisition includes:
– A spread history chart of the merger from announcement through eventual completion or failure.
– Every event as the merger progresses through the expiration of the HSR period, various regulatory approvals, shareholder votes, etc.
– News and SEC filings.
– A history of deal updates.
– And a whole lot more.
Disclaimer: Please conduct your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.
Editor’s Note: Baranjot Kaur contributed to this article